Erratum: Keratinocyte growth factor in acute lung injury to reduce pulmonary dysfunction - a randomised placebo-controlled trial (KARE): Study protocol. [Trials. (2013) (14)] DOI: 10.1186/1745-6215-14-51

Laurence J.M. Cross; Cecilia M. O'Kane; Cliona McDowell; Jospeh J. Elborn; Michael A. Matthay; Daniel F. McAuley

ArticleOPEN ACCESS

Erratum: Keratinocyte growth factor in acute lung injury to reduce pulmonary dysfunction - a randomised placebo-controlled trial (KARE): Study protocol. [Trials. (2013) (14)] DOI: 10.1186/1745-6215-14-51

Cross L
O'Kane C
McDowell C
et al.

Trials

DOI: 10.1186/s13063-017-1930-7

1Citations

9Readers

Abstract

In the original publication [1] the last sentence under the paragraph "Adverse event management" not correct. The correct version can be found here: "SAEs that occur between trial entry and up to 28 days after completion of the study drug will be reported".

Cite

CITATION STYLE

APA

Cross, L. J. M., O’Kane, C. M., McDowell, C., Elborn, J. J., Matthay, M. A., & McAuley, D. F. (2017, May 11). Erratum: Keratinocyte growth factor in acute lung injury to reduce pulmonary dysfunction - a randomised placebo-controlled trial (KARE): Study protocol. [Trials. (2013) (14)] DOI: 10.1186/1745-6215-14-51. Trials. BioMed Central Ltd. https://doi.org/10.1186/s13063-017-1930-7

Erratum: Keratinocyte growth factor in acute lung injury to reduce pulmonary dysfunction - a randomised placebo-controlled trial (KARE): Study protocol. [Trials. (2013) (14)] DOI: 10.1186/1745-6215-14-51

Abstract

Cite

Register to see more suggestions